Skip to main content

ETHNOS_APP

Home • Search • Journals • List 0

Prevalence and genotype distribution of human papillomavirus infection among women in Chengdu, China between 2020 and 2024

Bibliographic Data

ID22080221
AuthorsWenjuan Wang (0000-0001-9180-2823, University of Electronic Science and Technology of China), Junying Zhang (0000-0002-5665-4295, University of Electronic Science and Technology of China, corresponding author), Chaorong Mei (People's Hospital of Xinjiang Uygur Autonomous Region), Qianling Dai (0009-0001-1735-2606, Chengdu Women's and Children's Central Hospital), Yiling Cai (0000-0001-7477-6643, Chengdu Women's and Children's Central Hospital), Xiaoqing Wei (0000-0001-8963-3952, Chengdu Women's and Children's Central Hospital), Yan Li (0000-0001-6650-7726, Chengdu Women's and Children's Central Hospital, corresponding author)
Year2026
Volume13
Pages1740177-1740177
Publication date2026-01-05
Open AccessYes
TypeARTICLE
VenueFrontiers in Public Health (JOURNAL)
Journal identifiersISSN: 2296-2565 • E-ISSN: 2296-2565
PublisherFrontiers Media SA (PUBLISHER • CH)
DOI10.3389/fpubh.2025.1740177
PMID41561841
OpenAlexW7118179111
LanguageEN
References cited43

Background Cervical cancer remains a significant threat to women’s health globally. This study aimed to investigate the epidemiological characteristics of human papillomavirus (HPV) infection among women in Chengdu, China, between 2020 and 2024, to provide localized evidence for guiding cervical cancer prevention and control strategies. Methods A retrospective analysis was conducted using HPV screening data from 51,556 women at Chengdu Women’s and Children’s Central Hospital (CWCCH) between September 2020 and December 2024. Polymerase chain reaction-gene chip technology (PCR-GCT) was used to genotype 26 HPV types (17 high-risk [HR] and 9 low-risk [LR]). Statistical analyses included the chi-square test and Cochran-Armitage trend analysis. Results The overall HPV prevalence was 22.03% (11,360/51,556). The infection rate was significantly higher among gynecological outpatients (25.46%) than among participants undergoing routine health screening (13.97%). Single infections predominated (76.47%). The most prevalent HR-HPV genotypes were HPV-52 (3.89%), −16 (3.11%), −58 (2.58%), −51 (2.17%), and −39 (1.54%). A significant increasing trend in prevalence was observed from 2020 (18.70%) to 2024 (25.25%) ( p < 0.001). Age-specific prevalence showed a bimodal distribution, with the first peak in the ≤20 age group (49.35%) and a second smaller peak in the ≥61 age group (30.79%). Prevalence in spring, summer, and autumn was significantly higher than in winter. Notably, 39.40% of LR HPV infections involved co-infections with HR types. Conclusion The high and increasing HPV prevalence in Chengdu, along with its bimodal age distribution, seasonal variation, and frequent HR-LR co-infections—highlights the need for targeted interventions. HPV genotyping is recommended for patients with genital warts, particularly prior to procedures such as excision, to identify high-risk co-infections. A dual strategy of “vaccination and standardized screening” should be reinforced, including promoting the 9-valent vaccine (covering HPV-16/52/58) among young women and enhanced systematic screening for middle-aged and older women to control the second infection peak

China · Disease control · Genotype · Genotyping · HPV infection · Human papillomavirus · Sex organ · Cervical Cancer and HPV Research · Head and Neck Cancer Studies · Reproductive tract infections research

  • Sexual behaviour in context

    Open Access•Kaye Wellings, Martine Collumbien et al.•The Lancet•2006

  • Estimates of incidence and mortality of cervical cancer in 2018

    Open Access•Marc Arbyn, Elizabeth Weiderpa et al.•The Lancet Global Health•2020

  • Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer

    Nubia Muñoz, F Xavier Bosch et al.•New England Journal of Medicine•2003

  • Global Cancer Statistics 2020

    Open Access•Hyuna Sung, Adalberto M Filho et al.•CA: A Cancer Journal for Clinicians•2021

Highly citedNo

Tools

Open DOIOpen Access
Ethnos_APP • Open Source Project • MIT License • Frontend v2.0.0 • Privacy and Cookies • API Documentation: api.ethnos.app/docs • API Source Code: GitHub • DOI: 10.5281/zenodo.17049435 • Frontend Source Code: GitHub • DOI: 10.5281/zenodo.17050053 • cruz.rio.br • Expectantes Misericordiae